The recombinant zoster vaccine (RZV) Shingrix demonstrated effectiveness in preventing herpes zoster (HZ) and postherpetic neuralgia among adults aged 50 years or older with rheumatoid arthritis (RA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results